Compare Cassava Sciences Inc (FLNA) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Petróleo Brasileiro SA — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Petróleo Brasileiro SA trades at $17.45 (market cap $108.05B). The key difference: Petróleo Brasileiro SA is far larger — about 2033.3× Cassava Sciences Inc's market cap, and Petróleo Brasileiro SA pays a 9.87% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PBR | |
|---|---|---|
Market Cap | $53.14M | $108.05B |
Sector | Health | Technology |
52-Week High | $4.64 | $22.03 |
52-Week Low | $1.09 | $11.54 |
Enterprise Value | -$33.43M | $170.59B |
Dividend Yield | — | 9.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Petrobras (PBR) trades at $17.595, down 1.81% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with a P/E of 5.69, robust 21.47% net margin, and consistent dividend payments. Recent developments include strategic acquisitions in Africa and renewable energy investments totaling $1.2 billion. Earnings have shown mixed results, beating expectations in Q3 and Q4 2025 but missing in Q1 2026.
PBR presents an attractive value opportunity with discounted valuation metrics and 50% analyst buy ratings. Upside potential to the $23.90 consensus target offers significant return potential, though risks include oil price volatility and execution challenges in new projects. The company's strong cash flow generation supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
